Online PLR Content Marketing Sint Eustatius: Abilify

Abilify is a brand name of aripiprazole, approved by the FDA in the following formulation(s):

ABILIFY (aripiprazole - injectable; intramuscular)

Manufacturer: OTSUKA

Approval date: September 20, 2006

Strength(s): 9.75MG/1.3ML (7.5MG/ML) ^[RLD]

ABILIFY (aripiprazole - solution; oral)

Manufacturer: OTSUKA

Approval date: December 10, 2004

Strength(s): 1MG/ML ^[RLD]

ABILIFY (aripiprazole - tablet, orally disintegrating; oral)

Manufacturer: OTSUKA

Approval date: June 7, 2006

Strength(s): 10MG ^[RLD], 15MG

ABILIFY (aripiprazole - tablet; oral)

Manufacturer: OTSUKA

Approval date: November 15, 2002

Strength(s): 10MG ^[RLD], 15MG, 20MG, 2MG, 30MG, 5MG ^[RLD]

Has a generic version of Abilify been approved?

No. There is currently no therapeutically equivalent version of Abilify available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Abilify. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Carbostyril derivatives
Patent 5,006,528
Issued: April 9, 1991
Inventor(s): Oshiro; Yasuo & Sato; Seiji & Kurahashi; Nobuyuki
Assignee(s): Otsuka Pharmaceutical Co., Ltd.
A novel carbostyril derivative and salt thereof represented by the formula (1) ##STR1## (wherein R is a group of the formula ##STR2## ((wherein R.sup.1 is a C.sub.1- C.sub.3 alkoxy group)), a group of the formula ##STR3## ((wherein R.sup.2 and R .sup.3 are each, at the same time, a chlorine atom, a bromine atom; and R.sup.4 is a hydrogen atom or a chlorine atom)), 2-methyl-3-nitrophenyl group, 3,5-dichlorophenyl group, or a group of the formula ##STR4## ((wherein R.sup.5 is a chlorine atom or a bromine atom; and R.sup.6 is a methyl group)); the carbon-carbon bond between 3- and 4-position in the carbostyril skeleton is a single or double bond).
Patent expiration dates:
- October 20, 2014
  ✓
  Patent use: TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA
  ✓
  Drug substance
  ✓
  Drug product
- October 20, 2014
  ✓
  Patent use: ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION
  ✓
  Drug substance
  ✓
  Drug product
- April 20, 2015
  ✓
  Pediatric exclusivity

Aripiprazole oral solution
Patent 6,977,257
Issued: December 20, 2005
Inventor(s): Parab; Prakash V. & Chou; Joyc Tianw i
Assignee(s): Bristol-Myers Squibb Company
The present invention provides for a pharmaceutical solution suitable for oral administration comprising aripiprazole, a pharmaceutically suitable solvent system, one or more taste-enhancing/masking agents and one or more agents selected from the group consisting of lactic acid, acetic acid, tartaric acid and citric acid, wherein said solution has a pH from 2.5 to 4.5.
Patent expiration dates:
- April 24, 2022
  ✓
  Drug substance
  ✓
  Drug product
- October 24, 2022
  ✓
  Pediatric exclusivity

Aripiprazole complex formulation and method
Patent 7,115,587
Issued: October 3, 2006
Inventor(s): Nerurkar; Manoj & Naringrekar; Vijay
Assignee(s): Bristol-Myers Squibb Company
An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
Patent expiration dates:
- July 21, 2024
  ✓
  Patent use: TREATMENT OF SCHIZOPHRENIA
  ✓
  Drug substance
  ✓
  Drug product
- January 21, 2025
  ✓
  Pediatric exclusivity

Aripiprazole complex formulation and method
Patent 7,550,445
Issued: June 23, 2009
Inventor(s): Nerurkar; Manoj & Naringrekar; Vijay
Assignee(s): Bristol-Myers Squibb Company
An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
Patent expiration dates:
- July 21, 2024
  ✓
  Drug product
- January 21, 2025
  ✓
  Pediatric exclusivity

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- October 29, 2010 - TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
- November 16, 2010 - ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
- February 27, 2011 - TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS
- April 29, 2011 - PEDIATRIC EXCLUSIVITY
- May 6, 2011 - STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
- May 6, 2011 - ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
- August 27, 2011 - PEDIATRIC EXCLUSIVITY
- November 19, 2012 - TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
- February 16, 2014 - MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE

Online PLR Content Marketing Sint Eustatius

Sunday, April 26, 2009

Abilify